🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

FDA expands Pluvicto’s metastatic castration-resistant prostate cancer indication fda.gov/drugs/resource… The U.S. FDA 🇺🇸expanded the indication for lutetium Lu 177 vipivotide tetraxetan to include adults with PSMA-positive metastatic castration-resistant #ProstateCancer (mCRPC)

Theranostics – using nuclear medicine to both diagnose and treat a disease – is one of the great medical breakthroughs of the 20thcentury. Working in pairs, these radiopharmaceuticals both diagnose and treat diseases like cancer. Let's learn more!

PSMA-I&T vs PSMA-617: Is there a difference? Presentation by Matthias Eiber TU München. Written coverage by Helen Moon, MD Thrive with KP on UroToday > bit.ly/4cdmtDl PSMA and Beyond Conference #PSMAandBeyond2025

🚨 #PSMAandBeyond2025 🚨 Scott Tagawa Weill Cornell Medicine highlights the evolving role of PSMA-targeted antibodies in #prostatecancer, from beta to alpha radiotherapy! 🔬💡 💠 Lu-PSMA J591 shows promising PSA declines (87.5%) in #ProstACTGlobal 💠 Ac-PSMA therapies (Actinium) explore

Next-generation PSMA radioligands. Presentation by Martin Pomper, MD PhD UTSW Radiology. Written coverage by Helen Moon, MD Thrive with KP > bit.ly/4c9XroI PSMA and Beyond Conference #PSMAandBeyond2025

💧 Managing Dry Mouth in #ProstateCancer Sue Yom UCSF School of Medicine discusses strategies to address #xerostomia from PSMA-targeted therapies. Key takeaways: 🔹 Prevention: Cooling, botulinum injections, radioprotectants 🔹 Support: Xylitol, coconut oil, humidification, sialogogues

The Future of ADCs in #ProstateCancer Dr. John Lee UCLA reviews the challenges & progress of #AntibodyDrugConjugates: 🚧 Early ADCs failed due to antigen heterogeneity (PSMA volatility) 🔬 Hope in new agents: ARX-517 (auristatin payload) & FOR46 (CD46-targeted) show promise 🎯

GRPR and other peptides for targeting #ProstateCancer. Presentation by Andrei Iagaru, MD Stanford University. Written coverage by Zach Klaassen Georgia Cancer Center on UroToday > bit.ly/42bkGKp PSMA and Beyond Conference #PSMAandBeyond2025

🔬 #PSMAandBeyond2025 #Keynote: Michael Hofman Peter Mac Cancer Centre on combination therapy in #ProstateCancer 🚀 Trials show #LuPSMA + combo strategies improve outcomes: 📈 ENZA-p: LuPSMA + enzalutamide → ⬆️ PSA PFS (13 vs. 7.8 mo, HR 0.43) 🎯 LuPARP: LuPSMA + olaparib → 65% PSA50, 78% ORR

🚨 Beyond PSMA in #Prostate Cancer? 🚨 At #PSMAandBeyond2025, Dr. Robert Flavell UC San Francisco highlighted emerging targets for imaging & therapy: 🔬 #STEAP1 – Expressed in mCRPC, targeted by bispecifics & radiopharmaceuticals 🧬 #DLL3 – Found in neuroendocrine prostate cancer, new PET

See how dosimetry can be implemented in Theranostics despite resource limitations: bit.ly/4j9cmSs — For #WorldTheranosticsDay, we’re sharing insights all week that aim to help unlock the opportunities of #Theranostics. #RadiopharmaceuticalTherapy #RPT

Honored to present our work on PSMA-targeted alpha therapy (J591) at PSMA and Beyond Conference in LA—and thrilled to be selected as one of the Best Poster Presentations! 🏆🎉 Thanks to my mentors @JOsbMd Sandra Huicochea Castellanos & Scott Tagawa. Weill Cornell Medicine Radiology WCM Molecular Imaging and Therapeutics Weill Cornell Medicine Meyer Cancer Center

¹⁸F-FES PET is a successful biomarker for predicting the likelihood of success of endocrine therapy in patients with ER-positive #BreastCancer. ow.ly/WPMt50Vjv9Q #NuclearMedicine #PETscan Ashwin Singh Parihar, MBBS, MD

Members of our #GU team attended the PSMA and Beyond Conference last month, where they presented on the latest prostate-specific membrane antigen (#PSMA) #research coming out of Weill Cornell Medicine. Read more here: bit.ly/4jDPOJL #PSMAandBeyond2025

Characterization of effective half-life for instant single-time-point dosimetry using machine learning: ow.ly/m3fW50VnjR7 #NuclearMedicine #Dosimetry #MachineLearning Matthias Eiber Julia Brosch-Lenz Andrei Gafita

The origins and evelution of #PSMA! Martin Pomper, MD PhD UT Southwestern Medical Center retraces PSMA's journey—from LNCaP & cDNA cloning to the breakthrough that NAALADase is PSMA. His work with Alan Kozikowski paved the way for PSMA-11 & PSMA-617, transforming care for #mCRPC patients. #WatchNow on

📢 #ASCO25 | 3:00 PM–4:30 PM Clinical Science Symposium | Radioligand Therapy Remix: Finding the Right Patient for the Perfect Track | Jeremie Calais, MD, PhD dissects BULLSEYE (^177Lu‑PSMA‑617 in oHSPC), VIOLET (^161Tb‑PSMA‑I&T in mCRPC), and ENZA‑p (PSMA‑PET TTVol &

The UCLA Nuclear Medicine team is on the ground at #ASCO25 ! Every year, nuclear medicine & theranostics shine brighter on the #ASCO stage. UCLA UCLA Theranostics . #CancerResearch #NuclearMedicine #Theranostics

Radioligand therapy remix: Finding the right patient for the perfect track. Presentation by Jeremie Calais UCLA. #ASCO25 written coverage by Julian Chavarriaga University of Toronto > bit.ly/3Hkuewa ASCO

Do dosimetric behaviors and dose–effect relationships in ¹⁷⁷Lu-DOTATATE PRRT warrant consideration of alternative treatment strategies rather than the current fixed-activity protocol? ow.ly/7Uzv50VKM2t #NuclearMedicine #Dosimetry #RPTherapy Gunjan Kayal